The FDA granted priority review to pembrolizumab for the first-line treatment of patients with unresectable or metastatic melanoma, according to a press release from the drug’s manufacturer.
Publications
Frontline Pembrolizumab Receives FDA Priority Review in Melanoma
The FDA has granted a priority review to pembrolizumab (Keytruda) as a frontline treatment for patients with advanced melanoma, according to Merck, the manufacturer of the anti–PD-1 therapy. A final decision is scheduled from the FDA by December 19, 2015.
Identification of Risk Factors for Melanoma in Survivors of Non-Hodgkin Lymphoma
Risk for melanoma has been found to be increased in non-Hodgkin lymphoma (NHL) survivors. In a study reported in the Journal of Clinical Oncology, Lam et al found that T-cell–activating autoimmune diseases and fludarabine use were associated with an increased melanoma risk among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) but not among those with other NHL subtypes.
Organ transplant recipients may have increased risk for developing melanoma
Organ transplant recipients are twice as likely to develop melanoma compared with people who do not receive a transplant, according to a new study published in the Journal of Investigative Dermatology.